Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1356 versus glimepiride added to metformin in type 2 diabetes
2007-004585-40Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2007
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Linagliptin add-on to metformin with Glimepiride add-on to metformin (2 arms). Primary endpoint: Change from baseline in HbA1c at 104 weeks. Started Nov 2007; status: completed.
02
Drugs
linagliptinglimepiridemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-004585-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004585-40.